AU7161098A - Combinations of antigen and mucosal binding component for inducing specific immunological tolerance - Google Patents
Combinations of antigen and mucosal binding component for inducing specific immunological toleranceInfo
- Publication number
- AU7161098A AU7161098A AU71610/98A AU7161098A AU7161098A AU 7161098 A AU7161098 A AU 7161098A AU 71610/98 A AU71610/98 A AU 71610/98A AU 7161098 A AU7161098 A AU 7161098A AU 7161098 A AU7161098 A AU 7161098A
- Authority
- AU
- Australia
- Prior art keywords
- combinations
- antigen
- binding component
- tolerance
- specific immunological
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000427 antigen Substances 0.000 title abstract 3
- 102000036639 antigens Human genes 0.000 title abstract 3
- 108091007433 antigens Proteins 0.000 title abstract 3
- 230000001939 inductive effect Effects 0.000 title abstract 3
- 230000001900 immune effect Effects 0.000 title abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- QPJBWNIQKHGLAU-IQZHVAEDSA-N ganglioside GM1 Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 QPJBWNIQKHGLAU-IQZHVAEDSA-N 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000002459 sustained effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4418297P | 1997-04-23 | 1997-04-23 | |
| US4418497P | 1997-04-23 | 1997-04-23 | |
| US60044182 | 1997-04-23 | ||
| US60044184 | 1997-04-23 | ||
| PCT/US1998/008361 WO1998047529A1 (en) | 1997-04-23 | 1998-04-23 | Combinations of antigen and mucosal binding component for inducing specific immunological tolerance |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU7161098A true AU7161098A (en) | 1998-11-13 |
Family
ID=26721263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU71610/98A Abandoned AU7161098A (en) | 1997-04-23 | 1998-04-23 | Combinations of antigen and mucosal binding component for inducing specific immunological tolerance |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7097845B2 (OSRAM) |
| EP (1) | EP0977586B1 (OSRAM) |
| JP (1) | JP2001523249A (OSRAM) |
| AT (1) | ATE299711T1 (OSRAM) |
| AU (1) | AU7161098A (OSRAM) |
| DE (1) | DE69830900T2 (OSRAM) |
| DK (1) | DK0977586T3 (OSRAM) |
| WO (1) | WO1998047529A1 (OSRAM) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9800487D0 (en) * | 1998-01-09 | 1998-03-04 | Oratol Limited | Therapies |
| WO2001022995A1 (en) * | 1999-09-30 | 2001-04-05 | Novo Nordisk A/S | A method for preparing conjugates between an antigen and mucosal binding component |
| AU781909B2 (en) * | 2000-01-25 | 2005-06-23 | Board Of Regents Of The University Of Nebraska, The | Pre-transplant accommodated organs resistant to anti-donor immunity |
| US7897575B2 (en) * | 2000-05-24 | 2011-03-01 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment and prevention of vascular dementia |
| CA2447795A1 (en) * | 2001-05-23 | 2002-11-28 | Duotol Ab | Suppression of allergic reactions by transdermal administration of allergens in conjunction with or conjugated to toxin subunits or fragments thereof |
| EP2107069B1 (en) | 2003-08-05 | 2013-01-16 | Novo Nordisk A/S | Novel insulin derivatives |
| US20090074882A1 (en) | 2005-12-28 | 2009-03-19 | Novo Nordisk A/S | Insulin compositions and method of making a composition |
| JP5552046B2 (ja) | 2007-06-13 | 2014-07-16 | ノボ・ノルデイスク・エー／エス | インスリン誘導体を含有する薬学的製剤 |
| KR20110085985A (ko) | 2008-10-30 | 2011-07-27 | 노보 노르디스크 에이/에스 | 하루 한번 주사 빈도보다 적은 인슐린 주사를 사용한 진성 당뇨병의 치료 |
| JP6249773B2 (ja) * | 2010-05-10 | 2017-12-20 | ノヴォ ノルディスク アー／エス | インスリン−亜鉛錯体の調製方法 |
| BR112013010345A2 (pt) | 2010-10-27 | 2017-07-25 | Novo Nordisk As | tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção |
| JP2016519127A (ja) | 2013-04-30 | 2016-06-30 | ノヴォ ノルディスク アー／エス | 新規投与レジメン |
| US12605432B2 (en) | 2014-06-04 | 2026-04-21 | Diamyd Medical Ab | Combinations for antigen based therapy |
| US10335464B1 (en) | 2018-06-26 | 2019-07-02 | Novo Nordisk A/S | Device for titrating basal insulin |
| US12343383B2 (en) | 2019-07-12 | 2025-07-01 | Novo Nordisk A/S | High concentration insulin formulation |
| WO2022177890A1 (en) * | 2021-02-16 | 2022-08-25 | Applied Molecular Transport Inc. | Solid oral compositions with zinc |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4666837A (en) | 1982-05-24 | 1987-05-19 | Smithkline-Rit | DNA sequences, recombinant DNA molecules and processes for producing the A and B subunits of cholera toxin and preparations containing so-obtained subunit or subunits |
| DK97986A (da) * | 1985-03-08 | 1986-09-09 | Takeda Chemical Industries Ltd | Middel til inhibering af fordoejelse af sakkarid |
| US5399347A (en) | 1987-06-24 | 1995-03-21 | Autoimmune, Inc. | Method of treating rheumatoid arthritis with type II collagen |
| DE3856566T2 (de) | 1987-06-24 | 2004-06-24 | Brigham And Women's Hospital, Boston | Behandlung von Autoimmun-Erkrankungen durch orale Verabreichung von Autoantigenen |
| JPH02235823A (ja) | 1989-03-09 | 1990-09-18 | Watanabe Mitsuko | 抗アレルギー剤 |
| JP2891485B2 (ja) | 1989-09-25 | 1999-05-17 | 科学技術振興事業団 | 移植拒絶反応抑制剤 |
| WO1991008760A1 (en) | 1989-12-20 | 1991-06-27 | Brigham And Women's Hospital | Improved treatment of autoimmune diseases by aerosol administration of auto antigens |
| DE69127470T2 (de) | 1990-03-02 | 1998-02-19 | Autoimmune Inc | Verstärkung der unterdrückungsregulation von autoimmunkrankheiten durch orale oder enterale verabreichung von autoantigenen |
| CA2050425A1 (en) | 1990-09-03 | 1992-03-04 | Yoshiaki Uda | Pharmaceutical composition and its mucous use |
| JP3198390B2 (ja) * | 1990-09-03 | 2001-08-13 | 武田薬品工業株式会社 | 経粘膜用製剤 |
| IL99864A (en) | 1990-10-31 | 2000-11-21 | Autoimmune Inc | Compositions for suppressing transplant rejection in mammals which contain tissue donor derived MHC antigens |
| ES2190784T3 (es) | 1992-02-28 | 2003-08-16 | Autoimmune Inc | Supresion de enfermedades autoinmunes por antigenos espectadores. |
| US5453272A (en) | 1992-10-02 | 1995-09-26 | Alberta Research Council | Lectin derived carbohydrate binding-peptide |
| JP3109328B2 (ja) | 1993-05-19 | 2000-11-13 | ウシオ電機株式会社 | 加熱定着装置 |
| WO1994027634A1 (en) | 1993-06-02 | 1994-12-08 | Institute For Child Health Research | Cryptic peptides for use in inducing immunologic tolerance |
| US5681571A (en) * | 1993-10-08 | 1997-10-28 | Duotol Ab | Immunological tolerance-inducing agent |
| JP2847696B2 (ja) * | 1994-05-11 | 1999-01-20 | 田辺製薬株式会社 | プロピオフェノン誘導体及びその製法 |
| JP2847695B2 (ja) * | 1994-05-11 | 1999-01-20 | 田辺製薬株式会社 | 血糖降下剤 |
| IL111866A (en) | 1994-12-04 | 2005-03-20 | Yeda Res & Dev | Pharmaceutical compositions comprising the b-oligomer of pertussis toxin |
| JPH10512554A (ja) | 1995-01-10 | 1998-12-02 | ファイブローゲン，インコーポレーテッド | 免疫系媒介疾患の治療のためのコラーゲンに基づく方法および製剤 |
| AU6113896A (en) | 1995-06-05 | 1996-12-24 | Brigham And Women's Hospital | Use of oral tolerance to suppress both th1 and th2 immune re sponses and to suppress antibody production |
| GB9513733D0 (en) * | 1995-07-05 | 1995-09-06 | Univ Bristol | Therapeutic agents |
-
1998
- 1998-04-22 US US09/064,682 patent/US7097845B2/en not_active Expired - Fee Related
- 1998-04-23 EP EP98918742A patent/EP0977586B1/en not_active Expired - Lifetime
- 1998-04-23 JP JP54637498A patent/JP2001523249A/ja active Pending
- 1998-04-23 AT AT98918742T patent/ATE299711T1/de active
- 1998-04-23 AU AU71610/98A patent/AU7161098A/en not_active Abandoned
- 1998-04-23 WO PCT/US1998/008361 patent/WO1998047529A1/en not_active Ceased
- 1998-04-23 DE DE69830900T patent/DE69830900T2/de not_active Expired - Lifetime
- 1998-04-23 DK DK98918742T patent/DK0977586T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| DE69830900D1 (de) | 2005-08-25 |
| JP2001523249A (ja) | 2001-11-20 |
| ATE299711T1 (de) | 2005-08-15 |
| US20020119159A1 (en) | 2002-08-29 |
| DE69830900T2 (de) | 2006-05-24 |
| WO1998047529A1 (en) | 1998-10-29 |
| EP0977586A1 (en) | 2000-02-09 |
| EP0977586B1 (en) | 2005-07-20 |
| DK0977586T3 (da) | 2005-12-05 |
| US7097845B2 (en) | 2006-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69830900D1 (de) | Immunologische toleranz induzierende zusammensetzungen enthaltend antigen und mukosale bindende verbindungen | |
| NZ323973A (en) | Vaccine compositions for intranasal administration comprising chitosan and use thereof | |
| FI972945A0 (fi) | Antigeenien antamiseen soveltuvia koostumuksia | |
| DE69511379D1 (en) | Immunogens gegen gonadotropin releasing hormone | |
| BG102259A (en) | Compostions with controlled paroxetine release | |
| NZ306653A (en) | Isolated dna il-17 receptors | |
| IL111134A (en) | Immunological tolerance-inducing composition comprising a mucosa-binding molecule linked to a specific self-antigen/tolerogen | |
| WO1995034308A3 (en) | Adjuvant compositions comprising a mineral salt and another immunostimulating compound | |
| AU3121497A (en) | Methods of treating type i hypersensitivity using monophosphoryl lipid | |
| AU4005295A (en) | Compositions for the delivery of antigens | |
| IS5362A (is) | Kvalastillandi lyfjablöndur gerðar af efnasamböndum sem vinna gegn flogaveiki og aðferðir til að nota þær | |
| AU6783698A (en) | Polyaromatic antiviral compositions | |
| AU5933190A (en) | Glucan drug delivery system and adjuvant | |
| NZ308293A (en) | Antibacterial-wound healing compositions comprising a pyruvate, antioxidant and fatty acids | |
| NZ307055A (en) | Immunostimulating-wound healing compositions and methods for preparing and using same | |
| WO1996009805A3 (en) | Chitosan induced immunopotentiation | |
| GB9419979D0 (en) | Vaccine compositions | |
| BR9907883A (pt) | Composição de vacina, processo para eliciar uma resposta imune a um antìgeno de vìrus de herpes simplex, e, composição imunogênica | |
| PL311639A1 (en) | Stable gamma interferon composition in liquid form | |
| WO2000041508A3 (en) | Combination therapy of cancer by the activation of co-stimulatory molecules expressed by immune cells and cytokines | |
| BG103872A (en) | Glycoconjugates of 20(s)-camptotecin | |
| WO1996013498A3 (en) | L-erythrosyl nucleosides | |
| IL119225A (en) | Pharmaceutical compositions for the treatment of asthma in mammals | |
| WO2001017537A3 (en) | Methods and compositions for reducing immune response | |
| EP0282343A3 (en) | Method to stimulate the immune response to specific antigens |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |